Fig. 2From: Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trialKaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS). a PFS in the first-line (1 L) subgroup. b PFS in the second-line (2 L) subgroup. c OS in the 1 L subgroup. d OS in the 2 L subgroup. CI confidence interval, NE not evaluableBack to article page